Cardiovascular Inflammation

Donnerstag, 4. April | 09:30 - 11:00 Uhr | Posterbereich 9

Vorsitz/Chair: Michael Joner (München), Bernhard Schieffer (Marburg)


Nitroxolin is a novel inhibitor of NLRP3-dependent pyroptosis
C. Mäder (Leipzig)
Antiplatelet and anticoagulant compound (APAC) restricts thromboinflammation to ameliorates myocardial ischemia reperfusion injury
A. Arif (Leipzig)
Thrombin receptors as candidate therapeutic targets to prevent post-operative atrial fibrillation
I. Abu-Taha (Essen)
Double-stranded RNA sensing links antiviral innate immunity with pulmonary endothelial barrier integrity
G. Ciliberti (Mannheim)
Expression of human ACE2 in cardiomyocytes promotes COVID-19 and transcriptional cardiac remodeling and viral replication in lungs of K18-hACE2 transgenic mice
J. Duran (Heidelberg)
ARDS disrupts cardiac macrophage subsets
J. Grune (Berlin)
Atherosclerosis licenses for an exceeding immune response in COVID-19 disease
J. Leberzammer (Frankfurt am Main)
Optimized assessement of infectious endocarditis with a novel wire-injury based murine model
B. C. Bartsch (Bonn)
Diese Seite teilen